The 2019 mathematical oncology roadmap

Whether the nom de guerre is Mathematical Oncology, Computational or Systems Biology, Theoretical Biology, Evolutionary Oncology, Bioinformatics, or simply Basic Science, there is no denying that mathematics continues to play an increasingly prominent role in cancer research. Mathematical Oncology—defined here simply as the use of mathematics in cancer research—complements and overlaps with a number of other fields that rely on mathematics as a core methodology. As a result, Mathematical Oncology has a broad scope, ranging from theoretical studies to clinical trials designed with mathematical models. This Roadmap differentiates Mathematical Oncology from related fields and demonstrates specific areas of focus within this unique field of research. The dominant theme of this Roadmap is the personalization of medicine through mathematics, modelling, and simulation. This is achieved through the use of patient-specific clinical data to: develop individualized screening strategies to detect cancer earlier; make predictions of response to therapy; design adaptive, patient-specific treatment plans to overcome therapy resistance; and establish domain-specific standards to share model predictions and to make models and simulations reproducible. The cover art for this Roadmap was chosen as an apt metaphor for the beautiful, strange, and evolving relationship between mathematics and cancer.

[1]  A. Friedman,et al.  TNF-α inhibitor reduces drug-resistance to anti-PD-1: A mathematical model , 2020, PloS one.

[2]  B. Schrefler,et al.  Extension of a multiphase tumour growth model to study nanoparticle delivery to solid tumours , 2020, PloS one.

[3]  Marta F. Estrada,et al.  Zebrafish Avatars towards Personalized Medicine—A Comparative Review between Avatar Models , 2020, Cells.

[4]  Angela M. Jarrett,et al.  Forecasting tumor and vasculature response dynamics to radiation therapy via image based mathematical modeling , 2020, Radiation Oncology.

[5]  V. Zhdanov Spatio-temporal aspects of the interplay of cancer and the immune system , 2019, Journal of Biological Physics.

[6]  Sandra K. Johnston,et al.  Quantifying Uncertainty and Robustness in a Biomathematical Model–Based Patient-Specific Response Metric for Glioblastoma , 2019, JCO clinical cancer informatics.

[7]  Jacob G. Scott,et al.  Antibiotic collateral sensitivity is contingent on the repeatability of evolution , 2019, Nature Communications.

[8]  Robert A. Gatenby,et al.  Optimizing Cancer Treatment Using Game Theory: A Review , 2019, JAMA oncology.

[9]  Emmanuel Barillot,et al.  PhysiBoSS: a multi-scale agent-based modelling framework integrating physical dimension and cell signalling , 2018, bioRxiv.

[10]  H. Enderling,et al.  The accelerating quest for optimal radiation and immunotherapy combinations for local and systemic tumor control , 2018 .

[11]  Jason K. Sa,et al.  Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma , 2018, Neuro-oncology.

[12]  M. Ceccarelli,et al.  Single-cell transcriptome analysis of lineage diversity in high-grade glioma , 2018, Genome Medicine.

[13]  Artem Kaznatcheev Computational Complexity as an Ultimate Constraint on Evolution , 2019, Genetics.

[14]  Paul Macklin,et al.  Key challenges facing data-driven multicellular systems biology , 2018, GigaScience.

[15]  Sandra K. Johnston,et al.  Quantifying Uncertainty and Robustness in a Biomathematical Model Based Patient-Specific Response Metric for Glioblastoma , 2018, bioRxiv.

[16]  Kujtim Latifi,et al.  Predicting Patient-Specific Radiotherapy Protocols Based on Mathematical Model Choice for Proliferation Saturation Index , 2018, Bulletin of mathematical biology.

[17]  P. A. Futreal,et al.  Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal , 2018, Cell.

[18]  Robert A Gatenby,et al.  Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies , 2017, bioRxiv.

[19]  M. Medina Mathematical modeling of cancer metabolism. , 2018, Critical reviews in oncology/hematology.

[20]  T. Galla,et al.  Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies , 2018, JCO clinical cancer informatics.

[21]  Artem Kaznatcheev,et al.  Effective games and the confusion over spatial structure , 2018, Proceedings of the National Academy of Sciences.

[22]  O. Brawley,et al.  Screening and Early Detection , 2017 .

[23]  T. Graham,et al.  An evolutionary perspective on field cancerization , 2017, Nature Reviews Cancer.

[24]  M. Hochberg,et al.  Spatial competition constrains resistance to targeted cancer therapy , 2017, Nature Communications.

[25]  Joel s. Brown,et al.  Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer , 2017, Nature Communications.

[26]  Ignacio A. Rodriguez-Brenes,et al.  The role of telomere shortening in carcinogenesis: A hybrid stochastic-deterministic approach , 2017, bioRxiv.

[27]  Leland S. Hu,et al.  NIMG-74. RADIOMICS OF TUMOR INVASION 2.0: COMBINING MECHANISTIC TUMOR INVASION MODELS WITH MACHINE LEARNING MODELS TO ACCURATELY PREDICT TUMOR INVASION IN HUMAN GLIOBLASTOMA PATIENTS , 2017 .

[28]  Jeffrey West,et al.  Capitalizing on Competition: An Evolutionary Model of Competitive Release in Metastatic Castrate Resistant Prostate Cancer Treatment , 2017, bioRxiv.

[29]  Avlant Nilsson,et al.  Genome scale metabolic modeling of cancer. , 2017, Metabolic engineering.

[30]  Randy Heiland,et al.  PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems , 2017, bioRxiv.

[31]  P. Altrock,et al.  Extinction rates in tumour public goods games , 2017, Journal of The Royal Society Interface.

[32]  Sayed-Amir Marashi,et al.  A multiscale agent-based framework integrated with a constraint-based metabolic network model of cancer for simulating avascular tumor growth. , 2017, Molecular bioSystems.

[33]  David Basanta,et al.  Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer , 2017, Nature Ecology & Evolution.

[34]  B. Czerniecki,et al.  Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival , 2017, Breast Cancer Research.

[35]  Ramón Díaz-Uriarte,et al.  Cancer progression models and fitness landscapes: a many-to-many relationship , 2017, bioRxiv.

[36]  Sharon S. Hori,et al.  A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. , 2017, Cancer research.

[37]  P. Altrock,et al.  Extinction rates in tumor public goods games , 2017, bioRxiv.

[38]  Elena K. Kandror,et al.  Single-cell topological RNA-Seq analysis reveals insights into cellular differentiation and development , 2017, Nature Biotechnology.

[39]  Eduardo G Moros,et al.  The future of personalised radiotherapy for head and neck cancer. , 2017, The Lancet. Oncology.

[40]  Stacey D. Finley,et al.  Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer , 2017, Front. Physiol..

[41]  Jacob G. Scott,et al.  Somatic clonal evolution: A selection-centric perspective. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[42]  Jacob G. Scott,et al.  A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. , 2017, The Lancet. Oncology.

[43]  Pablo G. Cámara,et al.  Topological methods for genomics: present and future directions. , 2017, Current opinion in systems biology.

[44]  Naveen Garg,et al.  Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. , 2017, JCI insight.

[45]  Marc J. Williams,et al.  Quantification of subclonal selection in cancer from bulk sequencing data , 2018, Nature Genetics.

[46]  Alexander G. Fletcher,et al.  MultiCellDS: a standard and a community for sharing multicellular data , 2016, bioRxiv.

[47]  E. Dougherty,et al.  Big data need big theory too , 2016, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[48]  Alexander R A Anderson,et al.  Phase i trials in melanoma: A framework to translate preclinical findings to the clinic. , 2016, European journal of cancer.

[49]  M. Nowak,et al.  An exactly solvable, spatial model of mutation accumulation in cancer , 2016, Scientific Reports.

[50]  T E Yankeelov,et al.  Selection, calibration, and validation of models of tumor growth. , 2016, Mathematical models & methods in applied sciences : M3AS.

[51]  Oskar Hallatschek,et al.  Excess of mutational jackpot events in expanding populations revealed by spatial Luria–Delbrück experiments , 2016, Nature Communications.

[52]  Leland S. Hu,et al.  Radiogenomics to characterize regional genetic heterogeneity in glioblastoma , 2016, Neuro-oncology.

[53]  In-Hee Lee,et al.  Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.

[54]  J. McPherson,et al.  Coming of age: ten years of next-generation sequencing technologies , 2016, Nature Reviews Genetics.

[55]  Jianzhi Zhang,et al.  The fitness landscape of a tRNA gene , 2016, Science.

[56]  E. Hwang,et al.  Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. , 2016, Journal of the National Cancer Institute.

[57]  W. Reik,et al.  Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity , 2016, Genome Biology.

[58]  Erik Schultes,et al.  The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.

[59]  R. Gillies,et al.  Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer , 2016, Science Translational Medicine.

[60]  W. Koh,et al.  Single-cell genome sequencing: current state of the science , 2016, Nature Reviews Genetics.

[61]  Philipp M. Altrock,et al.  The mathematics of cancer: integrating quantitative models , 2015, Nature Reviews Cancer.

[62]  Teresa Wu,et al.  Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma , 2015, PloS one.

[63]  Thomas E Yankeelov,et al.  Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model. , 2015, Cancer research.

[64]  Yonghua Wang,et al.  Multi-scale modeling of cell survival and death mediated by the p53 network: a systems pharmacology framework. , 2015, Molecular bioSystems.

[65]  Alexander G. Fletcher,et al.  Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance , 2015, PLoS Comput. Biol..

[66]  Kujtim Latifi,et al.  A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation , 2015, Radiation oncology.

[67]  Jihyoun Jeon,et al.  A Multiscale Model Evaluates Screening for Neoplasia in Barrett’s Esophagus , 2015, PLoS Comput. Biol..

[68]  Robert J Gillies,et al.  Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. , 2015, Cancer research.

[69]  Thomas E Yankeelov,et al.  Toward a science of tumor forecasting for clinical oncology. , 2015, Cancer research.

[70]  M. Archetti,et al.  Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer , 2015, Proceedings of the National Academy of Sciences.

[71]  Kristin R. Swanson,et al.  Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas , 2014, PloS one.

[72]  Dominik Wodarz,et al.  Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) , 2014, Proceedings of the National Academy of Sciences.

[73]  K. Polyak,et al.  Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity , 2014, Nature.

[74]  D. Wodarz,et al.  Complex role of space in the crossing of fitness valleys by asexual populations , 2014, Journal of The Royal Society Interface.

[75]  Natalia L. Komarova,et al.  Dynamics of Cancer: Mathematical Foundations of Oncology , 2014 .

[76]  Abbas Shirinifard,et al.  The cell behavior ontology: describing the intrinsic biological behaviors of real and model cells seen as active agents , 2014, Bioinform..

[77]  Jakub Otwinowski,et al.  Inferring fitness landscapes by regression produces biased estimates of epistasis , 2014, Proceedings of the National Academy of Sciences.

[78]  William Hazelton,et al.  Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force , 2014, Annals of Internal Medicine.

[79]  B. Ross,et al.  Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules , 2014, Cell.

[80]  David Basanta,et al.  Edge effects in game-theoretic dynamics of spatially structured tumours , 2013, Journal of The Royal Society Interface.

[81]  Kristin R. Swanson,et al.  Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. , 2013, Cancer research.

[82]  Christopher S. Poultney,et al.  A physical sciences network characterization of non-tumorigenic and metastatic cells , 2013, Scientific Reports.

[83]  L. Hanin,et al.  Optimal screening schedules for prevention of metastatic cancer , 2013, Statistics in medicine.

[84]  Kristin R. Swanson,et al.  Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric , 2013, PloS one.

[85]  K. R. Swanson,et al.  From Patient-Specific Mathematical Neuro-Oncology to Precision Medicine , 2013, Front. Oncol..

[86]  J. R. Ledford Quantitative MRI in Cancer , 2012 .

[87]  S. Demaria,et al.  Radiation therapy to convert the tumor into an in situ vaccine. , 2012, International journal of radiation oncology, biology, physics.

[88]  B. Bot,et al.  Use of a novel patient-specific model of glioma growth kinetics to elucidate underlying biology as measured by gene expression microarray. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  H. Antti,et al.  LAB–OMICS AND PROGNOSTIC MARKERS , 2012 .

[90]  David Basanta,et al.  Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2012, Molecular pharmaceutics.

[91]  Alexander R A Anderson,et al.  Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: in Silico Modeling Integrates Imaging and Histology Nih Public Access Author Manuscript Introduction , 2011 .

[92]  Jacob G. Scott,et al.  Investigating prostate cancer tumour–stroma interactions: clinical and biological insights from an evolutionary game , 2011, British Journal of Cancer.

[93]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[94]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[95]  A. Deutsch,et al.  Studying the emergence of invasiveness in tumours using game theory , 2008, 0810.4724.

[96]  E. Luebeck,et al.  Evaluation of screening strategies for pre-malignant lesions using a biomathematical approach. , 2008, Mathematical biosciences.

[97]  V. Quaranta,et al.  Integrative mathematical oncology , 2008, Nature Reviews Cancer.

[98]  Steven A. Frank,et al.  Dynamics of Cancer , 2007 .

[99]  S. McDougall,et al.  Mathematical modeling of tumor-induced angiogenesis. , 2006, Annual review of biomedical engineering.

[100]  Nigel F. Delaney,et al.  Darwinian Evolution Can Follow Only Very Few Mutational Paths to Fitter Proteins , 2006, Science.

[101]  Douglas A. Creager,et al.  The Open Microscopy Environment (OME) Data Model and XML file: open tools for informatics and quantitative analysis in biological imaging , 2005, Genome Biology.

[102]  Tom R. Miller,et al.  PET: Molecular Imaging and Its Biological Applications. , 2005 .

[103]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[104]  D L S McElwain,et al.  A history of the study of solid tumour growth: The contribution of mathematical modelling , 2004, Bulletin of mathematical biology.

[105]  Catherine M Lloyd,et al.  CellML: its future, present and past. , 2004, Progress in biophysics and molecular biology.

[106]  Michael E. Phelps,et al.  PET: Molecular Imaging and Its Biological Applications , 2004 .

[107]  H. Othmer,et al.  Mathematical modeling of tumor-induced angiogenesis , 2004, Journal of mathematical biology.

[108]  C. Pedersen Unleashing the 'love' hormone , 2004, Nature Medicine.

[109]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[110]  Helen Parkinson,et al.  The MGED Ontology: A Framework for Describing Functional Genomics Experiments , 2003, Comparative and functional genomics.

[111]  M. Williams,et al.  Basic clinical radiobiology , 1994, British Journal of Cancer.

[112]  Danny R. Welch Tumor Heterogeneity--A 'Contemporary Concept' Founded on Historical Insights and Predictions. , 2016, Cancer research.

[113]  Ronald M. Summers,et al.  Kidney Tumor Growth Prediction by Coupling Reaction–Diffusion and Biomechanical Model , 2013, IEEE Transactions on Biomedical Engineering.

[114]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[115]  Facundo Mémoli,et al.  Topological Methods for the Analysis of High Dimensional Data Sets and 3D Object Recognition , 2007, PBG@Eurographics.

[116]  P M Nadkarni,et al.  The Common Data Elements for Cancer Research: Remarks on Functions and Structure , 2006, Methods of Information in Medicine.

[117]  Michael E. Phelps,et al.  PET , 2004, Springer New York.

[118]  M. Tattersall,et al.  Screening and Early Detection , 1994 .